NKTR Material Contracts | Nektar Therapeutics

Nektar Therapeutics Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

2026-08-14: Form 10-Q; Exhibit 10.2; Description First Amendment, dated May 7, 2026, to the Consulting Agreement between Nektar Therapeutics and FLG Partners, LLC..
2026-08-14: Form 10-Q; Exhibit 10.1; Description Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended++.
2024-08-09: Form 10-Q; Exhibit 10.1.6; Description Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended.++.
2024-05-10: Form 10-Q; Exhibit 10.1.6; Description Amendment No. 1 to Purchase and Sale Agreement, dated December 16, 2020, by and between entities managed by Healthcare Royalty Management, LLC and Nektar Therapeutics.+.

Filed	Form	Exhibit	Description
2026-08-14	10-Q	10.2	First Amendment, dated May 7, 2026, to the Consulting Agreement between Nektar Therapeutics and FLG Partners, LLC.
2026-08-14	10-Q	10.1	Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended++
2024-08-09	10-Q	10.1.6	Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended.++
2024-05-10	10-Q	10.1.6	Amendment No. 1 to Purchase and Sale Agreement, dated December 16, 2020, by and between entities managed by Healthcare Royalty Management, LLC and Nektar Therapeutics.+
2024-03-04	8-K	10.1	Securities Purchase Agreement, dated March 4, 2024, by and between Nektar Therapeutics and TCG Crossover Fund II, L.P.
2023-11-08	10-Q	10.6	Letter Agreement dated as of September 6, 2023 by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+
2023-08-09	10-Q	10.2	Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended.++
2023-08-09	10-Q	10.1	Employment Separation and Release Agreement effective as of June 19, 2023 by and between Nektar Therapeutics and Jillian B. Thomsen.++
2023-05-10	10-Q	10.1	Consulting Agreement between Nektar Therapeutics and FLG Partners, LLC dated April 7, 2023.
2022-08-05	10-Q	10.2	Employment Transition, Separation and Consultation Agreement, dated as of June 29, 2022, by and between Nektar Therapeutics and John Northcott.++
2022-08-05	10-Q	10.1	AMENDED AND RESTATED 2017 PERFORMANCE INCENTIVE PLAN
2022-03-01	10-K	10.40	Amendment No. 2 to Strategic Collaboration Agreement dated as of January 12, 2022, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+
2021-08-06	10-Q	10.1	Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended++
2021-02-26	10-K	10.39	Purchase and Sale Agreement, dated December 16, 2020, by and between entities managed by Healthcare Royalty Management, LLC and Nektar Therapeutics.+
2021-02-26	10-K	10.35	Co-Development Agreement, dated as of February 12, 2021, by and between SFJ Pharmaceuticals XII, L.P. and Nektar Therapeutics.+
2020-08-07	10-Q	10.2	Nektar Therapeutics Amended and Restated Employee Stock Purchase Plan++
2020-08-07	10-Q	10.1	Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended++
2020-05-08	10-Q	10.1	Amended and Restated Compensation Plan for Non-Employee Directors ++
2020-02-28	10-K	10.35	Amendment No. 1 to Strategic Collaboration Agreement dated as of January 9, 2020, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+
2020-02-28	10-K	10.19	Employment Agreement effective as of December 4, 2019, by and between Nektar Therapeutics and John Northcott.++
2020-02-28	10-K	10.17	Transition, Separation and General Release Agreement, dated as of January 9, 2020, by and between Stephen K. Doberstein and Nektar Therapeutics. ++
2019-11-07	10-Q	10.1	Separation, Consulting and General Release Agreement ++
2019-03-01	10-K	10.9	Forms of Stock Option Agreement, Performance Stock Option Agreement, Non-Employee Director Stock Option Agreement, Restricted Stock Unit Agreement, Performance Restricted Stock Unit Agreement, and Non-Employee Director Restricted Stock Unit Agreement under the Amended and Restated 2017 Performance Incentive Plan.++
2018-08-09	10-Q	10.1	Office Lease, effective as of May 31, 2018, by and between Kilroy Realty Finance Partnership, L.P., and Nektar Therapeutics.
2018-06-27	8-K	10.1	Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan
2018-05-10	10-Q	10.1	Strategic Collaboration Agreement, dated as of February 13, 2018, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+
2018-03-01	10-K	10.18	Separation and General Release Agreement dated as of December 20, 2017, by and between Nektar Therapeutics and Ivan Gergel, M.D.++
2018-03-01	10-K	10.9	Forms of Stock Option Agreement, Performance Stock Option Agreement, Non-Employee Director Stock Option Agreement, Restricted Stock Unit Agreement, Performance Restricted Stock Unit Agreement, and Non-Employee Director Restricted Stock Unit Agreement under the 2017 Performance Incentive Plan.++
2018-02-14	8-K	10.1	Share Purchase Agreement dated February 13, 2018, by and between Nektar Therapeutics and Bristol-Myers Squibb Company.
2017-11-08	10-Q	10.2	Lease Agreement dated August 4, 2017, as amended by the First Amendment to Lease dated as of August 29, 2017, by and between ARE-San Francisco No. 19, LLC and Nektar Therapeutics.
2017-11-08	10-Q	10.1	License Agreement effective as of August 23, 2017, by and between Eli Lilly and Company and Nektar Therapeutics.+
2017-06-15	8-K	10.1	Nektar Therapeutics 2017 Performance Incentive Plan
2016-11-04	10-Q	10.1	CLINICAL TRIAL COLLABORATION AGREEMENT
2016-08-04	10-Q	10.1	COLLABORATION AND LICENSE AGREEMENT
2015-12-17	8-K	10.4	Form of Performance Restricted Stock Unit Agreement
2015-12-17	8-K	10.3	Form of Restricted Stock Unit Agreement
2015-12-17	8-K	10.2	Form of Performance Stock Option Agreement
2015-12-17	8-K	10.1	Form of Stock Option Agreement
2015-10-06	8-K	10.3	Pledge and Security Agreement dated October 5, 2015 by and among Nektar Therapeutics and TC Lending, LLC.
2015-10-06	8-K	10.2	Indenture dated October 5, 2015 by and among Nektar Therapeutics, Wilmington Trust, National Association, and TC Lending, LLC.
2015-10-06	8-K	10.1	Purchase Agreement dated September 30, 2015 by and among Nektar Therapeutics and TC Lending, LLC and TAO Fund, LLC.
2015-06-17	8-K	10.1	2012 Performance Incentive Plan, as amended and restated
2015-02-26	10-K	10.16	I am pleased present to you with this offer letter
2014-06-27	8-K	10.1	Employee Stock Purchase Plan, as amended and restated
2014-02-27	10-K	10.29	TERM LOAN AND SECURITY AGREEMENT
2014-02-27	10-K	10.28	EMPLOYMENT TRANSITION AND GENERAL RELEASE AGREEMENT
2013-11-07	10-Q	10.1	AMENDMENT NO. 1 TO LICENSE AGREEMENT
2013-03-01	10-K	10.24	EXECUTED COPY PLEDGE AND SECURITY AGREEMENT
2013-03-01	10-K	10.7	COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS
2013-03-01	10-K	10.6	NEKTAR THERAPEUTICS 2012 PERFORMANCE INCENTIVE PLAN
2012-07-11	8-K	10.3	Escrow and Deposit Account Control Agreement dated July 11, 2012 among Nektar Therapeutics, Wells Fargo Bank, National Association, as collateral agent, and Wells Fargo Bank, National Association, as escrow agent.
2012-07-11	8-K	10.2	Pledge and Security Agreement dated July 11, 2012 by and between Nektar Therapeutics and Wells Fargo Bank, National Association.
2012-07-11	8-K	10.1	Indenture dated July 11, 2012 by and between Nektar Therapeutics and Wells Fargo Bank, National Association, including the form of 12.0% Senior Secured Note due 2017.
2012-07-10	8-K	10.1	Purchase Agreement dated July 3, 2012 by and among Nektar Therapeutics and the Initial Purchasers.
2012-07-03	8-K	10.1	Nektar Therapeutics 2012 Performance Incentive Plan
2012-05-04	10-Q	10.1	PURCHASE AND SALE AGREEMENT
2012-02-29	10-K	10.8	AMENDED AND RESTATED CHANGE OF CONTROL SEVERANCE BENEFIT PLAN
2012-02-29	10-K	10.7	2011 DISCRETIONARY INCENTIVE COMPENSATION POLICY
2012-02-29	10-K	10.5	AMENDED AND RESTATED COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS
2012-02-29	10-K	10.4	2008 EQUITY INCENTIVE PLAN
2012-02-29	10-K	10.3	2000 EQUITY INCENTIVE PLAN
2012-02-29	10-K	10.2	2000 NON-OFFICER EQUITY INCENTIVE PLAN
2011-04-11	8-K	10.1	NEKTAR THERAPEUTICS AMENDED AND RESTATED CHANGE OF CONTROL SEVERANCE BENEFIT PL
2011-03-01	10-K	10.31	SUPPLY, DEDICATED SUITE AND MANUFACTURING GUARANTEE AGREEMENT
2011-03-01	10-K	10.28	FOIA CONFIDENTIAL TREATMENT REQUESTED
2011-03-01	10-K	10.22	I am pleased present to you with this offer letter agreement (the “Letter Agreement”)
2011-03-01	10-K	10.16	NEKTAR THERAPEUTICS 2008 Equity Incentive Plan
2011-03-01	10-K	10.15	AMENDED AND RESTATED CHANGE OF CONTROL SEVERANCE BENEFIT PLAN
2011-03-01	10-K	10.14	Nektar Discretionary Incentive Compensation Policy
2011-03-01	10-K	10.12	years from the first commercial sale. Given the statistical probability of drug development success in the bio-pharmaceutical industry, drug development programs have only a 5% to 10% probability of reaching commercial success. If we
2011-03-01	10-K	10.7	2000 Equity Incentive Plan
2011-03-01	10-K	10.3	2000 Non-Officer Equity Incentive Plan
2010-12-30	8-K	10.1	SEPARATION AND GENERAL RELEASE AGREEMENT
2010-12-06	8-K	10.1	Nektar Therapeutics Amended and Restated Change of Control Severance Benefit Plan.
2010-07-06	8-K	10.1	Employee Stock Purchase Plan, as amended and restated
2010-03-03	10-K	10.16	Incentive Compensation Policy
2009-12-14	8-K	10.1	AMENDED AND RESTATED COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS
2009-11-30	8-K	10.1	Separation and General Release Agreement between Nektar Therapeutics and Randall W. Moreadith, M.D., Ph.D., dated November 23, 2009.
2009-11-05	10-Q	10.2	Omitted and Filed Separately with the Securities and Exchange
2009-11-05	10-Q	10.1	LICENSE
2009-03-06	10-K	10.35	Exhibit 10.35
2009-03-06	10-K	10.34	Exhibit 10.34
2009-03-06	10-K	10.29	Exhibit 10.29
2009-03-06	10-K	10.28	Exhibit 10.28
2009-03-06	10-K	10.27	Exhibit 10.27
2009-03-06	10-K	10.26	Exhibit 10.26
2009-03-06	10-K	10.22	Exhibit 10.22
2009-03-06	10-K	10.21	Exhibit 10.21
2009-03-06	10-K	10.20	Exhibit 10.20
2009-03-06	10-K	10.17	Exhibit 10.17
2009-01-02	8-K	10.1	Bonus and General Release Agreement dated as of December 27, 2008, by and between Nektar Therapeutics and Nevan C. Elam.

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
UroGen Pharma Ltd. (URGN)		$2.015B	-18.42
PERRIGO Co plc (PRGO)	Ireland	$2.038B	-0.79
Nuvation Bio Inc. (NUVB)	United States	$2.007B	-13.12
Generate Biomedicines, Inc. (GENB)	United States	$2.052B
Biohaven Ltd. (BHVN)	United States	$1.990B	-3.83
AGIOS PHARMACEUTICALS, INC. (AGIO)	United States	$1.962B	-5.38
Trevi Therapeutics, Inc. (TRVI)	United States	$2.091B	-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)	United States	$2.105B	-35.55
Braveheart Bio, Inc. (BRVE)	United States	$2.106B
Sarepta Therapeutics, Inc. (SRPT)	United States	$1.941B	-13.89